Background/Aim: Genetic variation in apolipoprotein E (ApoE) has a key role in lipid metabolism. However, its contribution to the amount and distribution of body fat is under investigation. The aim of this study was to analyze the association between genetic variation in ApoE and obesity-related traits in Mexican school children. Material and Methods: Anthropometric, body composition and physical activity measures were conducted using standard methods in 300 children (177 girls/123 boys) who fulfilled the inclusion criteria. DNA was isolated from saliva. ApoE genotypes were analyzed by allelic discrimination. The association between variation in ApoE and anthropometric and body composition measures was investigated using the General Linear Model. Results: The mean ± SD values for age, body mass index (BMI) and waist circumference (WC) were 9.05 ± 0.80 years, 19.01 ± 3.83 and 67.98 ± 10.97 cm, respectively. Approximately 46% of the participants were overweight or obese. A significant association between ApoE isoforms and WC was found after controlling for age, sex and the percentage of physical activity (p = 0.025). Significant main effects were found for vigorous physical activity and light physical activity influencing the adiposity-related BMI (p < 0.001) and WC (p = 0.044), respectively. Conclusions: Variation in ApoE and physical activity intensity were associated with adiposity-related phenotypes in Mexican school children.

Keywords:
Childhood obesity, Apolipoprotein E, Genetic variation, Body composition
1.
Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L, et al: Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, Instituto Nacional de Salud Pública, 2012.
2.
Shamah Levy T (ed): Encuesta Nacional de Salud en Escolares 2008. Cuernavaca, Instituto Nacional de Salud Pública, 2010.
3.
Page A, Cooper AR, Stamatakis E, Foster LJ, Crowne EC, Sabin M, et al: Physical activity patterns in nonobese and obese children assessed using minute-by-minute accelerometry. Int J Obes (Lond) 2005;29:1070-1076.
4.
Zarrouk F, Bouhlel E, Feki Y, Amri M, Shephard RJ: Physical activity patterns and estimated daily energy expenditures in normal and overweight Tunisian schoolchildren. J Sports Sci Med 2009;8:83-88.
5.
Manco M, Dallapiccola B: Genetics of pediatric obesity. Pediatrics 2012;130:123-133.
6.
Comuzzie AG, Williams JT, Martin LJ, Blangero J: Searching for genes underlying normal variation in human adiposity. J Mol Med (Berl) 2001;79:57-70.
7.
Butte NF, Comuzzie AG, Cole SA, Mehta NR, Cai G, Tejero M, et al: Quantitative genetic analysis of the metabolic syndrome in Hispanic children. Pediatr Res 2005;58:1243-1248.
8.
Guerra A, Rego C, Castro EM, Seixas S, Rocha J: Influence of apolipoprotein E polymorphism on cardiovascular risk factors in obese children. Ann Nutr Metab 2003;47:49-54.
9.
Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al: Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-1311.
10.
Taimela S, Lehtimaki T, Porkka KV, Rasanen L, Viikari JS: The effect of physical activity on serum total and low-density lipoprotein cholesterol concentrations varies with apolipoprotein E phenotype in male children and young adults: the Cardiovascular Risk in Young Finns Study. Metabolism 1996;45:797-803.
11.
Medina-Urrutia AX, Cardoso-Saldana GC, Zamora-Gonzalez J, Liria YK, Posadas-Romero C: Apolipoprotein E polymorphism is related to plasma lipids and apolipoproteins in Mexican adolescents. Hum Biol 2004;76:605-614.
12.
Khan TA, Shah T, Prieto D, Zhang W, Price J, Fowkes GR, et al: Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol 2013;42:475-492.
13.
Rall SC Jr, Weisgraber KH, Mahley RW: Human apolipoprotein E: the complete amino acid sequence. J Biol Chem 1982;257:4171-4178.
14.
Weisgraber KH, Rall SC Jr, Mahley RW: Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-9083.
15.
Kypreos KE, Karagiannides I, Fotiadou EH, Karavia EA, Brinkmeier MS, Giakoumi SM, et al: Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity. FEBS J 2009;276:5720-5728.
16.
Huang ZH, Reardon CA, Mazzone T: Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006;55:3394-3402.
17.
Huang ZH, Minshall RD, Mazzone T: Mechanism for endogenously expressed ApoE modulation of adipocyte very low density lipoprotein metabolism: role in endocytic and lipase-mediated metabolic pathways. J Biol Chem 2009;284:31512-31522.
18.
Huang ZH, Espiritu DJ, Uy A, Holterman AX, Vitello J, Mazzone T: Adipose tissue depot-specific differences in adipocyte apolipoprotein E expression. Metabolism 2011;60:1692-1701.
19.
Ellis JA, Ponsonby AL, Pezic A, Williamson E, Cochrane JA, Dickinson JL, et al: APOE genotype and cardio-respiratory fitness interact to determine adiposity in 8-year-old children from the Tasmanian Infant Health Survey. PLoS One 2011;6:e26679.
20.
Petkeviciene J, Smalinskiene A, Luksiene DI, Jureniene K, Ramazauskiene V, Klumbiene J, et al: Associations between apolipoprotein E genotype, diet, body mass index, and serum lipids in Lithuanian adult population. PLoS One 2012;7:e41525.
21.
Srinivasan SR, Ehnholm C, Wattigney WA, Bao W, Berenson GS: The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis 1996;123:33-42.
22.
Lohman TG, Roche AF, Martorell R (eds): Anthropometric Standardization Reference Manual. Champaign, Human Kinetics Books, 1988.
23.
Schaefer F, Georgi M, Zieger A, Scharer K: Usefulness of bioelectric impedance and skinfold measurements in predicting fat-free mass derived from total body potassium in children. Pediatr Res 1994;35:617-624.
24.
Petersen AC, Crockett L, Richards M, Boxer A: A self-report measure of pubertal status: reliability, validity, and initial norms. J Youth Adolesc 1988;17:117-133.
25.
Petersen AC, Crockett L: Pubertal development score categories. E-mail to Hernández-Armenta CI and Rodríguez-Carmona Y, October 2013, unpublished.
26.
Evenson KR, Catellier DJ, Gill K, Ondrak KS, McMurray RG: Calibration of two objective measures of physical activity for children. J Sports Sci 2008;26:1557-1565.
27.
WHO: Growth reference 5-19 years. BMI-for-age (5-19 years). 2007. http://www.who.int/groWHtRef/who2007_bmi_for_age/en/index.html (cited August 20, 2013).
28.
Fernández JR, Redden DT, Pietrobelli A, Allison DB: Waist circumference percentiles in nationally representative samples of Africa-American, European-American, and Mexican-American children and adolescents. J Pediatr 2004;145:439-444.
29.
Elizondo-Montemayor L, Serrano-Gonzalez M, Ugalde-Casas PA, Bustamante-Careaga H, Cuello-Garcia C: Waist-to-height: cutoff matters in predicting metabolic syndrome in Mexican children. Metab Syndr Relat Disord 2011;9:183-190.
30.
McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM: Body fat reference curves for children. Int J Obes (Lond) 2006;30:598-602.
31.
Rivera J, Cuevas L, Shamah T, Villalpando S, Ávila MA, Jiménez A: Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, Instituto Nacional de Salud Pública, 2006.
32.
Ríos-García B, Romero-Zertuche D, Olivares-Gonzalez N, Osante-Miranda G: Prevalencia de obesidad infantil en un grupo de población escolar de 6 a 13 años en la Ciudad de México. Rev Hosp Jua Méx 2008;75:109-116.
33.
Haffner SM, Stern MP, Miettinen H, Robbins D, Howard BV: Apolipoprotein E polymorphism and LDL size in a biethnic population. Arterioscler Thromb Vasc Biol 1996;16:1184-1188.
34.
Gamboa R, Hernandez-Pacheco G, Hesiquio R, Zuniga J, Masso F, Montano LF, et al: Apolipoprotein E polymorphism in the Indian and Mestizo populations of Mexico. Hum Biol 2000;72:975-981.
35.
Gamboa R, Vargas-Alarcon G, Medina-Urrutia A, Cardoso-Saldana G, Hernandez-Pacheco G, Zamora-Gonzalez J, et al: Influence of the apolipoprotein E polymorphism on plasma lipoproteins in a Mexican population. Hum Biol 2001;73:835-843.
36.
Gamboa R, Huesca-Gomez C, Perez-Mendez O, Cruz-Robles D, Fragoso JM, Juarez-Cedillo T, et al: Apolipoprotein E polymorphisms in Mexican patients with coronary artery disease. Clin Chem Lab Med 2008;46:481-485.
37.
Browning LM, Hsieh SD, Ashwell M: A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr Res Rev 2010;23:247-269.
38.
Savva SC, Tornaritis M, Savva ME, Kourides Y, Panagi A, Silikiotou N, et al: Waist circumference and waist-to-height ratio are better predictors of cardiovascular disease risk factors in children than body mass index. Int J Obes Relat Metab Disord 2000;24:1453-1458.
39.
Arbones-Mainar JM, Johnson LA, Altenburg MK, Maeda N: Differential modulation of diet-induced obesity and adipocyte functionality by human apolipoprotein E3 and E4 in mice. Int J Obes (Lond) 2008;32:1595-1605.
40.
Corella D, Ordovas JM: Single nucleotide polymorphisms that influence lipid metabolism: interaction with dietary factors. Annu Rev Nutr 2005;25:341-390.
41.
Haerens L, Deforche B, Maes L, Cardon G, De Bourdeaudhuij I: Physical activity and endurance in normal weight versus overweight boys and girls. J Sports Med Phys Fitness 2007;47:344-350.
42.
Mitchell JA, Mattocks C, Ness AR, Leary SD, Pate RR, Dowda M, et al: Sedentary behavior and obesity in a large cohort of children. Obesity (Silver Spring) 2009;17:1596-1602.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.